Cloud-Clone ELISA kit supported osteoporosis study in Nature Biomedical Engineering

Cloud-Clone says its FGF2 ELISA kit helped researchers quantify bone-metabolism markers in a July 2026 osteoporosis study published in Nature Biomedical Engineering. The work from East China University of Science and Technology introduced a sulfated polysaccharide designed to rebalance bone turnover without suppressing key repair signals.

Why it matters: - The study points to a new osteoporosis strategy that aims to reduce harmful bone resorption without shutting down the repair pathways needed for bone formation and angiogenesis. - Cloud-Clone’s reagent support highlights how measurement tools can shape the quality of data behind high-impact biomedical research. - The paper appeared in a Nature family journal, a sign the findings reached a top-tier scientific audience.

What happened: - A research team led by Academician Changsheng Liu at East China University of Science and Technology published findings on July 30, 2026 in Nature Biomedical Engineering. - The team designed an engineered sulfated polysaccharide called 26SCS. - The compound targets the K97 site on the RANK protein and is described as producing “peak-clipping and valley-filling” effects on bone metabolism. - Cloud-Clone’s FGF2 ELISA Kit, Catalog No. CEA551Ra, was used to quantify bone-metabolism-related factors in the project.

The details: - The study reports that 26SCS restored 115% of bone mass in osteoporotic mice. - The compound preserved PDGF-BB secretion from pre-osteoclasts, which matters for angiogenesis-coupled bone repair. - Researchers measured VEGF, PDGF-BB, FGF2, TGF-β1 and other analytes to assess bone formation and angiogenesis. - Cloud-Clone’s FGF2 kit was used to detect basic fibroblast growth factor in distal-femur tissue homogenates from rats. - The kit’s reported performance includes 87% to 95% sample recovery in serum, 85% to 101% in EDTA-plasma and 78% to 94% in heparin-treated plasma. - Cloud-Clone lists intra-assay CV below 10% and inter-assay CV below 12% for the kit. - Linear-dilution recovery reportedly exceeded 80% across dilution ranges. - The kit uses a competitive-inhibition ELISA platform with monoclonal antibodies and is compatible with serum, plasma, tissue homogenates and cell-culture supernatants. - Cloud-Clone says the assay supports accurate detection in complex bone-tissue matrices.

Between the lines: - The paper’s main scientific shift is not simply to stimulate or suppress bone turnover, but to fine-tune both sides of the remodeling process. - The study argues that sulfated polysaccharides should be judged by spatial arrangement of sulfate groups, not just total sulfate density. - Cloud-Clone is using the publication to showcase the credibility of its detection portfolio in demanding translational studies. - The company also framed the result as evidence that validated reagents can materially affect reproducibility and confidence in multi-target experiments.

What's next: - The research suggests further work on sequence-defined sulfated polysaccharides as drug candidates for bone disease. - Cloud-Clone said it will keep expanding its research-service capacity, including animal housing, custom animal-model generation, pharmacokinetic assessment, and pharmacology and toxicology testing. - The company also continues to position itself as a supplier of antibodies, recombinant proteins, multiplex panels and other research tools for multi-pathway studies.

The bottom line: - The Nature Biomedical Engineering paper advances a more precise osteoporosis concept, and Cloud-Clone’s ELISA kit was part of the measurement workflow that supported the findings.